Marevan

Warfarin Sodium, the active ingredient in Marevan, is an anticoagulant presented as a oral tablet for oral use. It treats and prevents blood clots in conditions such as venous thromboembolism, atrial fibrillation, and prosthetic heart valve patients.

GNH USA supplies Marevan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Marevan (warfarin sodium) is used in the management of thromboembolic disorders by inhibiting clot formation.

- Venous thromboembolism: prevents recurrence and treats existing clots. - Atrial fibrillation: reduces risk of stroke and systemic embolism. - Prosthetic heart valves: lowers incidence of valve‑related thromboembolic complications.

Warfarin sodium may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Minor bleeding: gums, nosebleeds, easy bruising. - Gastrointestinal upset: nausea, abdominal discomfort. - Skin rash: mild erythema or itching. - Hair loss: temporary thinning.

Serious or Rare Side Effects: - Major hemorrhage: internal bleeding, intracranial hemorrhage. - Skin necrosis: painful skin lesions, especially early in therapy. - Allergic reactions: anaphylaxis, angioedema.

Marevan requires careful monitoring and patient education to minimize bleeding risk.

- INR monitoring: adjust dose based on regular International Normalized Ratio testing. - Dietary vitamin K: maintain consistent intake of vitamin K‑rich foods. - Drug interactions: review concomitant medications that affect coagulation. - Pregnancy: avoid use unless benefits outweigh risks; consult specialist. - Surgery or invasive procedures: discontinue before major surgery to reduce bleeding risk. - Store at ambient temperature: keep below 25°C in original container, protect from moisture and light.

Warfarin interacts with many medicines; some combinations must be avoided while others need close observation.

Major Interactions (Avoid): - Amiodarone: markedly increases warfarin effect, risk of severe bleeding. - Rifampicin: reduces anticoagulant effect, may lead to clotting. - NSAIDs (e.g., ibuprofen): additive bleeding risk, avoid concurrent use.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., clopidogrel): increase bleeding tendency, monitor INR. - Certain antibiotics (e.g., trimethoprim‑sulfamethoxazole): may enhance anticoagulation, check labs. - Herbal supplements (e.g., ginkgo, garlic): can affect warfarin metabolism, advise caution.